| Title | Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023 |
|---|---|
| Authors | Antunes, Liliana ; Mazagatos, Clara ; Martínez-Baz, Iván ; Gomez, Verónica ; Borg, Maria-Louise ; Petrović, Goranka ; Duffy, Róisín ; Dufrasne, François E ; Dürrwald, Ralf ; Lazar, Mihaela ; Jančorienė, Ligita ; Oroszi, Beatrix ; Husa, Petr ; Howard, Jennifer ; Melo, Aryse ; Pozo, Francisco ; Pérez-Gimeno, Gloria ; Castilla, Jesús ; Machado, Ausenda ; Džiugytė, Aušra ; Karabuva, Svjetlana ; Fitzgerald, Margaret ; Fierens, Sébastien ; Tolksdorf, Kristin ; Popovici, Silvia-Odette ; Mickienė, Auksė ; Túri, Gergő ; Součková, Lenka ; Nicolay, Nathalie ; Rose, Angela MC |
| DOI | 10.2807/1560-7917.ES.2024.29.3.2300708 |
| Full Text |
|
| Is Part of | Eurosurveillance.. Stockholm : European Centre for Disease Control and Prevention (ECDC). 2024, vol. 29, iss. 3, art. no. 2300708, p. [1-8].. ISSN 1025-496X. eISSN 1560-7917 |
| Abstract [eng] | We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter. |
| Published | Stockholm : European Centre for Disease Control and Prevention (ECDC) |
| Type | Journal article |
| Language | English |
| Publication date | 2024 |
| CC license |
|